GSK, Sanofi to supply 200 million doses of Covid-19 vaccine to COVAX
GlaxoSmithKline (GSK) and Sanofi have entered into a statement of intent with Gavi to supply 200 million doses of their adjuvanted recombinant protein-based Covid-19 vaccine to the COVAX Facility.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.